national-clinical-guidelines-for-stroke-fourth-edition
national-clinical-guidelines-for-stroke-fourth-edition
national-clinical-guidelines-for-stroke-fourth-edition
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
5.8 Treatment of unusual causes of <strong>stroke</strong><br />
In about 25% of <strong>stroke</strong> cases, and more commonly in younger patients, no cause is<br />
evident on initial screening. Other causes that should be considered include<br />
paroxysmal atrial fibrillation, which may require 3- or 7-day cardiac monitoring to<br />
detect, intracranial arterial disease, cervical artery dissection, antiphospholipid<br />
syndrome and other prothrombotic conditions, and patent <strong>for</strong>amen ovale (PFO). In<br />
patients where no cause is identified and particularly where there is a history of<br />
venous or arterial thrombosis or early miscarriage, a thrombophilia screen should be<br />
per<strong>for</strong>med.<br />
5.8.1 Vertebral artery disease<br />
5.8.1.1 Recommendation<br />
5.8.1.2 Source<br />
A Angioplasty and stenting of the vertebral artery should only be per<strong>for</strong>med in the<br />
context of a <strong>clinical</strong> trial.<br />
A Consensus<br />
5.8.2 Intracranial arterial disease<br />
5.8.2.1 Recommendations<br />
5.8.2.2 Source<br />
A Patients with symptomatic intracranial stenosis should be offered an intensive<br />
antiplatelet regime (eg aspirin and clopidogrel) <strong>for</strong> 3 months in addition to usual<br />
recommendations <strong>for</strong> secondary prevention intervention and lifestyle modification.<br />
B Endovascular intervention <strong>for</strong> intracranial stenosis should not be per<strong>for</strong>med except in<br />
the context of a <strong>clinical</strong> trial.<br />
A–B Chimowitz et al 2011<br />
5.8.3 Patent <strong>for</strong>amen ovale<br />
Evidence to recommendation<br />
5 Secondary prevention<br />
Patent <strong>for</strong>amen ovale is found in 25% of the healthy population and it is there<strong>for</strong>e difficult<br />
to know whether the finding of a PFO is relevant in a patient with cryptogenic <strong>stroke</strong>. It is<br />
more likely if there is a good history of the <strong>stroke</strong> occurring during or shortly after a<br />
Valsalva manoeuvre or where there are recurrent <strong>stroke</strong>s in different arterial territories. No<br />
adequate trials have been per<strong>for</strong>med to indicate whether treatment should be antiplatelet<br />
drugs, anticoagulation or closure of the PFO. Natural history studies would suggest a low<br />
recurrence rate that probably does not justify the risk of closure unless there is recurrent<br />
© Royal College of Physicians 2012 75